QD
QDEL.US QuidelOrtho Corp
- Market cap
- USD 677M
- P/E
- -
- P/B
- 0.39x
- ROE
- -17.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QDEL.US undervalued?
Graham numberThe Graham number of QuidelOrtho Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
QuidelOrtho Corp fundamental analysis
No fundamental analysis for QuidelOrtho Corp yet.
QuidelOrtho Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About QuidelOrtho Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spre…
Full company profileQuidelOrtho Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
QuidelOrtho Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 192M | 278M | 522M | 535M | 1.66B | 1.70B | 3.27B | 3.00B | 2.78B | 2.73B | 2.49B |
| Gross Profit | 118M | 156M | 316M | 321M | 1.35B | 1.28B | 1.94B | 1.50B | 1.29B | 1.27B | 1.10B |
| Operating Income | -4.44M | 9.55M | 95.9M | 92.7M | 1.06B | 906M | 844M | 139M | -1.96B | -919M | -75.6M |
| EBITDA | 18.8M | 40.3M | 134M | 140M | 1.10B | 953M | 1.09B | 607M | -1.49B | -488M | 378M |
| Net Income | -13.8M | -8.17M | 74.2M | 72.9M | 810M | 704M | 549M | -10.1M | -2.05B | -1.13B | -318M |
| EPS | -0.42 | -0.24 | 1.74 | 1.69 | 19 | 16 | 9.56 | -0.15 | -31 | -17 | -4.63 |
| Balance Sheet | |||||||||||
| Total Assets | 388M | 935M | 806M | 911M | 1.87B | 2.43B | 8.86B | 8.56B | 6.42B | 5.77B | 5.78B |
| Total Liabilities | 188M | 708M | 381M | 351M | 538M | 501M | 3.92B | 3.56B | 3.44B | 3.85B | 3.99B |
| Shareholders' Equity | 201M | 227M | 426M | 560M | 1.33B | 1.93B | 4.93B | 5.01B | 2.98B | 1.92B | 1.79B |
| Cash & Short-term Investments | 170M | 36.1M | 43.7M | 52.8M | 490M | 829M | 345M | 167M | 98.3M | 202M | 192M |
| Total Debt | 148M | 397M | 108M | 112M | 109M | 139M | 2.85B | 2.61B | 2.68B | 2.83B | 3.12B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.8M | 27.7M | 136M | 134M | 630M | 806M | 885M | 280M | 83.0M | 105M | -165M |
| Capital Expenditure | 11.9M | 17.5M | 31.7M | 27.2M | 64.9M | 293M | 141M | 209M | 195M | 188M | 107M |
| Free Cash Flow | -94.0K | 10.2M | 105M | 107M | 565M | 513M | 744M | 70.9M | -112M | -83.0M | -273M |
| Ratios | |||||||||||
| ROE | -6.9% | -3.6% | 17.4% | 13.0% | 60.8% | 36.5% | 11.1% | -0.2% | -68.8% | -58.9% | -17.8% |
| ROA | -3.6% | -0.9% | 9.2% | 8.0% | 43.3% | 29.0% | 6.2% | -0.1% | -31.9% | -19.6% | -5.5% |
| Net Profit Margin | -7.2% | -2.9% | 14.2% | 13.6% | 48.8% | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% | -12.8% |
| Debt to Equity | 0.74x | 1.75x | 0.25x | 0.20x | 0.08x | 0.07x | 0.58x | 0.52x | 0.90x | 1.48x | 1.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
QuidelOrtho Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 255M | 7.56 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns QuidelOrtho Corp
- Insiders 0.92%
- Institutions 99.08%
- Public & others 0.00%
- Shares outstanding 68.6M
- Free float 61.2M
Top funds holding QDEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.13M | 6.02% | +0.06% | Oct 2026 |
| Avantis US Small Cap Value ETF | 3.59M | 5.23% | +0.62% | Oct 2026 |
| Invesco Small Cap Value A | 3.10M | 4.52% | 0.00% | Sep 2026 |
| Fidelity Value | 2.25M | 3.27% | -40.98% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.17M | 3.17% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.76M | 2.56% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.54M | 2.25% | -1.49% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 1.00M | 1.46% | +0.86% | Sep 2026 |
| Fidelity US All Cap Series F | 947K | 1.38% | +11.67% | Jun 2026 |
| Neuberger Intrinsic Value I | 869K | 1.27% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 832K | 1.21% | -28.39% | Sep 2026 |
| Fidelity Small Cap Index | 764K | 1.11% | +1.28% | Aug 2026 |
| PIMCO RAE US S Instl | 730K | 1.06% | +3.77% | Jun 2026 |
| iShares Russell 2000 Value ETF | 647K | 0.94% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 625K | 0.91% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Value ETF | 568K | 0.83% | 0.00% | Oct 2026 |
| Fidelity Value Strategies | 545K | 0.79% | -41.81% | Sep 2026 |
| Neuberger US Sm Cp Intrs Val USD I Acc | 431K | 0.63% | +1.14% | Jul 2026 |
| Kempen (Lux) Global Small-Cap I | 411K | 0.60% | 0.00% | Jun 2026 |
| Vanguard Russell 2000 ETF | 400K | 0.58% | +1.04% | Sep 2026 |
Top institutions holding QDEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 11.2M | 16.33% | +7.21% | Jun 2026 |
| FMR Inc | 7.36M | 10.73% | +11.72% | Jun 2026 |
| Newtyn Management LLC | 6.63M | 9.66% | +45.33% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.14M | 6.03% | +2.57% | Jun 2026 |
| American Century Companies Inc | 3.93M | 5.72% | +18.73% | Sep 2026 |
| Neuberger Berman Group LLC | 3.53M | 5.15% | +130.96% | Jun 2026 |
| Amvescap Plc. | 3.47M | 5.06% | +11.42% | Jun 2026 |
| Rubric Capital Management LP | 3.31M | 4.82% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.07M | 4.47% | +0.57% | Jun 2026 |
| State Street Corp | 2.98M | 4.34% | +6.89% | Jun 2026 |
| Paradigm Capital Management, Inc. | 2.52M | 3.68% | +65.26% | Jun 2026 |
| Private Management Group Inc | 2.07M | 3.02% | +49.51% | Jun 2026 |
| Geode Capital Management, LLC | 1.83M | 2.67% | +6.94% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.74M | 2.54% | -69.03% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.68M | 2.44% | +63.70% | Jun 2026 |
| Segall Bryant & Hamill | 1.35M | 1.96% | -12.82% | Jun 2026 |
| Gagnon Securities LLC | 1.30M | 1.89% | +26.03% | Sep 2026 |
| Allianz Asset Management AG | 1.13M | 1.64% | +11.91% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.06M | 1.55% | -55.86% | Jun 2026 |
| Rice Hall James & Associates, LLC | 1.06M | 1.55% | +3.62% | Jun 2026 |
QuidelOrtho Corp company profile
- Company name
- QuidelOrtho Corp
- Ticker
- QDEL.US
- Exchange
- USA Stocks
- Listed since
- Feb 1, 1991
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,500
- Fiscal year end
- December
- Address
- 9975 Summers Ridge Road, San Diego, CA, United States, 92121
- Phone
- 858 552 1100
- Website
- quidelortho.com
About QuidelOrtho Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
QuidelOrtho Corp management
10- Mr. Brian J. BlaserPresident, CEO & Director · born 1965
- Mr. Philip D. McLellanChief Operations Officer · born 1970
- Mr. Jonathan P. Siegrist Ph.D.Executive VP of Research & Development and CTO · born 1982
- Mr. Micah Young CPAChief Financial Officer & Principal Financial Officer · born 1979
- Mr. Nathaniel B. Sisitsky Esq.Chief Legal Officer & Corporate Secretary · born 1974
- Ms. Lisa S. HayesVice President of Global Marketing & Corporate Communications
- Mr. Bryan M. HansonExecutive VP of Global Portfolio Management and Marketing · born 1980
- Mr. Erich WolffExecutive Vice President of Strategy & Corporate Development
- Mr. Ronald Lee BowmanChief Human Resources Officer · born 1979
- Ms. Iris LinHead of JAPAC (Japan, ASPAC & China)